Therefore, HBV-transgenic mice were treated with DEN and CCl4 to induce HBV-associated liver cancer, followed by intraperitoneal injection of OSMI-1 or intravenous injection of pSECC lentiviruses expressing sgRNA targeting Ythdf2. Administration of OSMI-1 or pSECC-sgYthdf2 resulted in decelerated liver tumorigenesis, as indicated by smaller tumor masses and nodules, as well as lower serum levels of ALT and AST (Fig. 7b-f). This evidence concerns the gene YTHDF2 and liver cancer.